Breaking News
The Deep State's Get-Out-Of-Jail-Free Card
Why Not Stop Mass Immigration into the United States?
French President Macron's Popularity Falls to Record Low of 16 Per Cent
Top Signs You're Heading for a Quagmire
Top Tech News
NASA Super Light Solar Sail Project Will Be 12-40 Times Lighter and Faster
Space Telescope Interferometer to Image Exoplanet Continents
Twenty-five years of "temporary": how 9/11 built a surveillance state Americans never vote
I'll Never Buy Another WALMART Battery!
Shoei GT-Air 3 Smart helmet drops with built-in AR for $1,500
Freezable titanium plate keeps your cooler chilled way longer than ice packs
Review: Affordable thermal device is made for discovering life outdoors
AI Whistleblower Tells Tucker How AI Could Kill All Humans by 2040
You Hate Flock? Well There's More...
Will Spiking Diesel Prices Drive Autonomous Trucking?
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.